As debate about the usefulness and ethics of generative artificial intelligence (AI) continues, the pharmaceutical industry needs to consider the advantages it can offer, especially for inc
This week, pharmaphorum heads to the Big Apple for the FT US Pharma and Biotech Summit, a one-day event where executives from some of the world’s top pharma companies will come together to
Creating healthcare interventions and technological solutions that work is hard enough. But when the goal is sustainable system-wide improvement, it’s the easy part.
In this third instalment of the five-part, festive series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Mark Andrews, investment director of life sciences funds at Brit
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.